Hydralazine Modifies A beta Fibril Formation and Prevents Modification by Lipids in Vitro

[摘要]：Lipid oxidative damage and amyloid beta (A beta) misfolding contribute to Alzheimer's disease (AD) pathology. Thus, the prevention of oxidative damage and A beta misfolding are attractive targets for drug discovery. At present, no AD drugs approved by the Food and Drug Administration (FDA) prevent or halt disease progression. Hydralazine, a smooth muscle relaxant, is a potential drug candidate for AD drug therapy as it reduces A beta production and prevents oxidative damage via its antioxidant hydrazide group. We evaluated the efficacy of hydralazine, and related hydrazides, in reducing (1) A beta misfolding and (2) A beta protein modification by the reactive lipid 4-hydroxy-2-nonenal (HNE) using transmission electron microscopy and Western blotting. While hydralazine did not prevent A beta aggregation as measured using the protease protection assay, there were more oligomeric species observed by electron microscopy. Hydralazine prevented lipid modification of A beta, and A beta was used as a proxy for classes of proteins which either misfold or are modified by HNE. All of the other hydrazides prevented lipid modification of A beta and also did not prevent A beta aggregation. Surprisingly, a few of the compounds, carbazochrome and niclosamide, appeared to augment A beta formation. Thus, hydrazides reduced lipid oxidative damage, and hydralazine additionally reduced A beta misfolding. While hydralazine would require specific chemical modifications for use as an AD therapeutic itself (to improve blood brain barrier permeability, reduce vasoactive side effects, and optimization for amyloid inhibition), this study suggests its potential merit for further AD drug development.

[全文传递流程]：

一般上传文献全文的时限在1个工作日内